Robin Schaefer1, Heather-Marie A Schmidt2, Giovanni Ravasi3, Antons Mozalevskis4, Bharat B Rewari5, Frank Lule6, Kouadio Yeboue7, Anne Brink8, Nabeel Mangadan Konath5, Mukta Sharma5, Nicole Seguy4, Joumana Hermez9, Ahmed S Alaama9, Naoko Ishikawa8, Boniface Dongmo Nguimfack10, Daniel Low-Beer10, Rachel Baggaley10, Shona Dalal10. 1. Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland. Electronic address: schaeferr@who.int. 2. Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland; UNAIDS Regional Office for Asia and the Pacific, Bangkok, Thailand. 3. Pan-American Health Organization, Washington, DC, USA. 4. World Health Organization Regional Office for Europe, Copenhagen, Denmark. 5. World Health Organization Regional Office for South-East Asia, New Delhi, India. 6. World Health Organization Regional Office for Africa, Brazzaville, Republic of the Congo. 7. World Health Organization Regional Office for Africa, Inter-Country Support Team, Ouagadougou, Burkina Faso. 8. World Health Organization Regional Office for the Western Pacific, Manila, Philippines. 9. World Health Organization Regional Office for the Eastern Mediterranean, Cairo, Egypt. 10. Global HIV, Hepatitis and STIs Programmes, World Health Organization, Geneva, Switzerland.
Abstract
BACKGROUND: In 2016, the UN General Assembly set a global target of 3 million oral pre-exposure prophylaxis (PrEP) users by 2020. With this target at an end, we aimed to assess global trends in the adoption of WHO PrEP recommendations into national guidelines and numbers of PrEP users, defined as people who received oral PrEP at least once in a given year, and to estimate future trajectories of PrEP use. METHODS: In this global summary and forecasting study, data on adoption of WHO PrEP recommendations and numbers of PrEP users were obtained through the Global AIDS Monitoring system and WHO regional offices. Trends in these indicators for 2016-19 by region and for 2019 by country were described, including by gender and priority populations where data were available. PrEP user numbers were forecasted until 2023 by selecting countries with at least 3 years of PrEP user data as example countries in each region to represent possible future PrEP user trajectories. PrEP user growth rates observed in example countries were applied to countries in corresponding regions under different scenarios, including a COVID-19 disruption scenario with static global PrEP use in 2020. FINDINGS: By the end of 2019, 120 (67%) of 180 countries with data had adopted the WHO PrEP recommendations into national guidelines (23 in 2019 and 30 in 2018). In 2019, there were about 626 000 PrEP users across 77 countries, including 260 000 (41·6%) in the region of the Americas and 213 000 (34·0%) in the African region; this is a 69% increase from about 370 000 PrEP users across 66 countries in 2018. Without COVID-19 disruptions, 0·9-1·1 million global PrEP users were projected by the end of 2020 and 2·4-5·3 million are projected by the end of 2023. If COVID-19 disruptions resulted in no PrEP user growth in 2020, the projected number of PrEP users in 2023 is 2·1-3·0 million. INTERPRETATION: Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified delivery, PrEP could contribute to ending AIDS by 2030. FUNDING: Unitaid, Bill & Melinda Gates Foundation, and WHO.
BACKGROUND: In 2016, the UN General Assembly set a global target of 3 million oral pre-exposure prophylaxis (PrEP) users by 2020. With this target at an end, we aimed to assess global trends in the adoption of WHO PrEP recommendations into national guidelines and numbers of PrEP users, defined as people who received oral PrEP at least once in a given year, and to estimate future trajectories of PrEP use. METHODS: In this global summary and forecasting study, data on adoption of WHO PrEP recommendations and numbers of PrEP users were obtained through the Global AIDS Monitoring system and WHO regional offices. Trends in these indicators for 2016-19 by region and for 2019 by country were described, including by gender and priority populations where data were available. PrEP user numbers were forecasted until 2023 by selecting countries with at least 3 years of PrEP user data as example countries in each region to represent possible future PrEP user trajectories. PrEP user growth rates observed in example countries were applied to countries in corresponding regions under different scenarios, including a COVID-19 disruption scenario with static global PrEP use in 2020. FINDINGS: By the end of 2019, 120 (67%) of 180 countries with data had adopted the WHO PrEP recommendations into national guidelines (23 in 2019 and 30 in 2018). In 2019, there were about 626 000 PrEP users across 77 countries, including 260 000 (41·6%) in the region of the Americas and 213 000 (34·0%) in the African region; this is a 69% increase from about 370 000 PrEP users across 66 countries in 2018. Without COVID-19 disruptions, 0·9-1·1 million global PrEP users were projected by the end of 2020 and 2·4-5·3 million are projected by the end of 2023. If COVID-19 disruptions resulted in no PrEP user growth in 2020, the projected number of PrEP users in 2023 is 2·1-3·0 million. INTERPRETATION: Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified delivery, PrEP could contribute to ending AIDS by 2030. FUNDING: Unitaid, Bill & Melinda Gates Foundation, and WHO.
Authors: Michelle Cespedes; Moupali Das; J Carlo Hojilla; Jill Blumenthal; Karam Mounzer; Moti Ramgopal; Theo Hodge; Thiago S Torres; Charles Peterson; Senzokuhle Shibase; Ayana Elliott; A C Demidont; Larkin Callaghan; C Chauncey Watson; Christoph Carter; Alex Kintu; Jared M Baeten; Onyema Ogbuagu Journal: PLoS One Date: 2022-06-03 Impact factor: 3.752
Authors: Katherine M Jia; Hallie Eilerts; Olanrewaju Edun; Kevin Lam; Adam Howes; Matthew L Thomas; Jeffrey W Eaton Journal: J Int AIDS Soc Date: 2022-01 Impact factor: 5.396
Authors: Luh Putu Lila Wulandari; Shi Yi He; Christopher K Fairley; Benjamin R Bavinton; Heather Marie-Schmidt; Virginia Wiseman; Rebecca Guy; Weiming Tang; Lei Zhang; Jason J Ong Journal: EClinicalMedicine Date: 2022-07-09
Authors: Heather-Marie Ann Schmidt; Michelle Rodolph; Robin Schaefer; Rachel Baggaley; Meg Doherty Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Robin Schaefer; Pedro Henrique Amparo da Costa Leite; Ronaldo Silva; Quarraisha Abdool Karim; Christopher Akolo; Carlos F Cáceres; Inês Dourado; Kimberly Green; Anita Hettema; Elske Hoornenborg; Smarajit Jana; Bernhard Kerschberger; Hally Mahler; Sindy Matse; Hamish McManus; Jean-Michel Molina; Sushena Reza-Paul; Iskandar Azwa; Maryam Shahmanesh; Doug Taylor; Hamid Vega-Ramirez; Valdiléa G Veloso; Rachel Baggaley; Shona Dalal Journal: Lancet HIV Date: 2022-03-07 Impact factor: 16.070